In a dominant mouse ethylnitrosurea mutagenesis screen for genes regulating erythropoiesis, we identified a pedigree with a novel microcytic hypochromia caused by a V235G missense mutation in Dynamin 2 (Dnm2). Mutations in Dnm2, a GTPase, are highly disease-specific and have been implicated in four forms of human diseases: centronuclear myopathy, Charcot-Marie Tooth neuropathy and, more recently, T-cell leukaemia and Hereditary Spastic Paraplegia, but red cell abnormalities have not been reported to date. The V235G mutation lies within a crucial GTP nucleotide-binding pocket of Dnm2, and resulted in defective GTPase activity and incompatibility with life in the homozygous state. Dnm2 is an essential mediator of clathrin-mediated endocytosis, which is required for the uptake of transferrin (Tf) into red cells for incorporation of haem. Accordingly, we observed significantly reduced Tf uptake by Dnm2 +/V235G cells, which led to impaired endosome formation. Despite these deficiencies, surprisingly all iron studies were unchanged, suggesting an unexplained alternative mechanism underlies microcytic anaemia in Dnm2 +/ V235G mice. This study provides the first in vivo evidence for the requirements of Dnm2 in normal erythropoiesis.
Summary
In a dominant mouse ethylnitrosurea mutagenesis screen for genes regulating erythropoiesis, we identified a pedigree with a novel microcytic hypochromia caused by a V235G missense mutation in Dynamin 2 (Dnm2). Mutations in Dnm2, a GTPase, are highly disease-specific and have been implicated in four forms of human diseases: centronuclear myopathy, Charcot-Marie Tooth neuropathy and, more recently, T-cell leukaemia and Hereditary Spastic Paraplegia, but red cell abnormalities have not been reported to date. The V235G mutation lies within a crucial GTP nucleotide-binding pocket of Dnm2, and resulted in defective GTPase activity and incompatibility with life in the homozygous state. Dnm2 is an essential mediator of clathrin-mediated endocytosis, which is required for the uptake of transferrin (Tf) into red cells for incorporation of haem. Accordingly, we observed significantly reduced Tf uptake by Dnm2 +/V235G cells, which led to impaired endosome formation. Despite these deficiencies, surprisingly all iron studies were unchanged, suggesting an unexplained alternative mechanism underlies microcytic anaemia in Dnm2 +/ V235G mice. This study provides the first in vivo evidence for the requirements of Dnm2 in normal erythropoiesis.
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The study of mutant rodent strains with inherited microcytic hypochromic anaemia has provided key insights into the regulators of iron metabolism. For example, the divalent metal transporter 1 (Dmt1), which mediates absorption of iron by villus enterocytes and exports iron from endosomes into the cytoplasm was first identified by study of the mk mouse and the Belgrade rat, which have microcytic, hypochromic anaemia (Fleming et al, 1997 (Fleming et al, , 1998 . Forward genetic screens using chemical mutagens such as ethylnitrosurea (ENU) have aided this effort, revealing important functional motifs and residues in other key players of iron metabolism. This was exemplified by the discovery of the fragile-red mouse strain, which pinpointed a tyrosine residue in the ferrireductase Steap3 that is required for its endosomal localization (Lambe et al, 2009 ). These and other animal models have demonstrated the essential role of iron uptake through the transferrin (Tf) cycle in developing erythrocytes. The transferrin-iron (Tf-Fe) complex binds to the membrane-spanning transferrin receptor 1 (CD71; TfR1), which is then internalised within a clathrin-coated pit (CCP) via clathrin-mediated endocytosis (CME). Cleavage of the CCP from the plasma membrane allows fusion with intracellular endosomes. Inside the endosome, ferric iron (Fe 3+ ) is reduced to ferrous iron (Fe 2+ ) by Steap3 for transport out of the endosome by DMT1, where it is shuttled to the mitochondria for incorporation into haem (for the formation of haemoglobin) and iron-sulphur cluster-containing proteins, or stored in the cytoplasm as ferritin (the storage unit of iron). Following release of ferric iron, the apoprotein-Tf-TfR1 complex is recycled back to the plasma membrane with the help of Sec15l, another regulator of iron metabolism that was first identified in a mutant mouse strain exhibiting microcytic anaemia (Lim et al, 2005) . The unique dependence of the Tf-cycle in normal erythropoiesis was demonstrated by gene targeting studies of TfR1 in mice. Homozygous deletion of TfR1 resulted in failure of definitive erythropoiesis and lethality by embryonic day (E) 12Á5 (Levy et al, 1999) . The time point of lethality indicated that the Tf cycle is not essential for primitive erythropoiesis, or the development of most organs, where iron uptake is mediated by TfR1-independent mechanisms (Ned et al, 2003; Li et al, 2009) .
Dynamin 2 (DNM2), a member of the large GTPase family, plays an essential role in CME (Damke et al, 1994; Ferguson et al, 2009) . DNM2 is the only isoform of the classical dynamins (which includes DNM1, DNM2 and DNM3) whose expression can be detected in almost all cells (Cook et al, 1994; Sontag et al, 1994) . DNM2 contains five distinct protein domains, each imparting a specific function during vesicle budding: the GTPase domain, responsible for GTP binding and hydrolysis (Song et al, 2004) ; the middle domain, functioning in dynamin self-assembly (Ramachandran et al, 2007) ; the plekstrin homology (PH) domain, which interacts with phospholipids (Achiriloaie et al, 1999) ; the GTPase effector domain (GED), responsible for mediating dynamin self-assembly and direct interactions with the GTPase domain (Sever et al, 1999) ; and the proline-rich domain, which binds to the SH3 domain of BAR domaincontaining proteins during dynamin recruitment in CME (Shpetner et al, 1996) . Inherited mutations in DNM2 have been linked to three autosomal dominant human diseases: centronuclear myopathy (CNM), the axonal or intermediate form of Charcot-Marie Tooth neuropathy (CMT) and hereditary spastic paraplegia (HSP). In CMT, mutations almost always occur in the middle domain, whilst in CNM, they are predominantly found in the middle and PH domains (Bitoun et al, 2005; Zuchner et al, 2005) . In contrast, recently described DNM2 mutations in HSP patients have thus far been detected in the GED domain (Sambuughin et al, 2015) . In vitro functional characterisation of mutant proteins from CMT and CMN suggests that these mutations behave in a dominant negative and disease-specific manner (Durieux et al, 2010; Liu et al, 2011; Sidiropoulos et al, 2012) . To date, no mutations have been identified in the GTPase domain in these disorders.
Through an ENU mutagenesis screen for regulators of erythropoiesis, we have identified a novel mouse strain harbouring a missense mutation in the GTPase domain of Dnm2, in which the predominant phenotype of heterozygotes is a microcytic anaemia of unknown aetiology. This study provides the first evidence that Dnm2 plays a role in developing erythrocytes.
Methods

Gene mapping and mice
A G1 pedigree (RBC12; Dnm2 V235G ) displaying microcytosis was identified in an ENU mutagenesis screen described previously (Brown et al, 2013) . Mapping was performed by outcrossing affected heterozygotes to wild-type Balb/cJ mice. Tail genomic DNA from G2 and subsequent generation animals was subjected to simple sequence length polymorphism based genome-wide scanning followed by SNP fine mapping at the Australian Genome Research Facility (AGRF, Melbourne, Australia). The candidate interval was refined to 17Á71-24Á24 Mb on chromosome 9. Dynamin 2 knock-out mice (Ferguson et al, 2009) 
Genomic custom-capture array and next generation sequencing
Massively parallel sequencing and bioinformatics of RBC12 was performed by the AGRF. A custom genomic capture array was constructed by Roche Sequencing Solutions, Madison, WI, USA to enrich for exons within the 17Á71-24Á24 Mb candidate interval on chromosome 9. Oligonucleotide sequences based on the C57BL/6 reference strain sequence that specifically hybridised to only one location in the genome were designed; 80% coverage of the target region was achieved. Genomic DNA was prepared by the AGRF from liver samples harvested from affected RBC12 mice. Massively parallel sequencing was performed using the Illumina HiSeq platform (Illumina, Can Diego, CA, USA) and the University of California, Santa Cruz (UCSC), CA, USA C57BL/6 reference sequence was used for assembly and alignment of the reads.
Genotyping
The Dnm2 V235G mice were genotyped by polymerase chain reaction (PCR) amplification of the region spanning the V235G mutation using primers: forward (5 0 -GCAGTCCAA TTCCCAACAATCG-3 0 ) and reverse (5 0 -CTGGGTGGGA-GAGGAAGAATTTC-3 0 ); followed by restriction enzyme 
Phenylhydrazine studies
Animals were administered phenylhydrazine (PHZ; 60 mg/ kg; Sigma Aldrich, Sydney, Australia) on two consecutive days by intraperitoneal injection. Blood (50 ll) was collected from the tail vein twice per week over 3 weeks for haematocrit measurement.
Erythroid progenitor assays
Numbers of Blast-Forming Units-erythroid (BFU-e) in bone marrow were assessed by culture in methylcellulose (Methocel, Fluka Biochemika, Sydney, Australia) containing the cytokines murine interluekin 3, rat stem cell factor and erythropoietin at final concentrations of 5, 50 ng/ml and 8 units/ml, respectively, as previously described (Slape et al, 2012) .
Quantitative-PCR
Total RNA was extracted from organs using TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions, followed by cDNA amplification of 1 lg total RNA using the Reverse Transcription Kit (Roche Diagnostics Australia, Castle Hill, Australia). Quantitative-PCR (q-PCR) was performed on a LightCycler 480II (Roche Diagnostics Australia) using the GoTaq qPCR Master Mix (Promega, Madison, WI, USA). Expression of target genes was normalized to Actb (b-actin) and data was presented as relative expression compared to the wild-type controls. Gene-specific primer sequences were as follows: Dnm2, 5 0 -GGACTTGGC-
Western blotting
Cells were lysed in buffer containing complete protease inhibitors (Roche Diagnostics Australia), separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a nitrocellulose membrane.
Immunoblotting was performed with antibodies against DNM2 (sc-6400; Santa Cruz, Dallas, TX, USA) and actin as the loading control (5125; Cell Signalling, Danvers, MA, USA). Immunoblots were detected using the ECL chemilluminescence kit (Amersham Systems, Little Chalfont, UK) on the FluorChem imaging system (ProteinSimple, San Jose, CA, USA) with the appropriate HRP-linked secondary antibody (GE Healthcare, Little Chalfont, UK).
Transplantation assays
Whole bone marrow cells were harvested from 10-week-old Dnm2 +/V235G and wild-type littermate mice. Recipients were lethally irradiated with 2 doses of 550 Rads administered 2 h apart, and transplanted with 2 9 10 6 donor cells by intravenous injection. All transplanted animals were fed antibiotic-treated water.
Plasmids
For the expression of human DNM2 variant 2 (NM_001005361.2) in mammalian cells (for endocytic assays) and insect cells (for GTPase assays) the expression vectors pEGFP-C1 (BD Biosciences Clontech, Mountain View, CA, USA) and pIEx-6 (Novagen â , Darmstadt, Germany), respectively, were used. DNM2-V235G, R465W, K562E and K44A mutants were generated by oligonucleotide site-directed mutagenesis (QuikChange â II Site-Directed Mutagenesis Kit; Agilent Technologies, Mulgrave, Vic., Australia).
Dynamin expression, purification and GTPase assays
Dynamin was transiently expressed in Sf21 insect cells in a WAVE(tm) bioreactor at the Commonwealth Scientific and Industrial Research Organisation Fermentation Facility in Melbourne, Australia. Pellets were harvested 48 h after transfection and frozen on dry ice and stored at À80°C until used for dynamin purification. For purification, insect cell pellets were defrosted into lysis buffer containing HEPES (20 mmo/ l, pH 7Á4), EGTA (1 mmo/l), EDTA (1 mmo/l), Triton X-100 (1% v/v), NaCl (250 mmo/l), Leupeptin (1 lg/ml), phenylmethanesulfonyl fluoride (PMSF; 50 lmol/l) and EDTA-free protease inhibitor cocktail (Roche Diagnostics Australia). Suspensions were sonicated 3 times for 1 min each using a probe sonifier and incubated on ice for 30 min.
Lysates were clarified by centrifugation at 17 000 9 g for 1 h at 4°C and incubated with glutathione beads conjugated to GST-tagged Amphiphysin 2 SH3 domains for 45 min at 4°C.
Glutathione beads were washed with column buffer containing HEPES (20 mmo/l, pH 7Á4), NaCl (250 mmo/l) and dithiothreitol (DTT; 1 mmo/l). Dynamin was eluted from the beads in elution buffer containing PIPES (piperazine-N, N 0 -bis(2-ethanesulfonic acid); 20 mmo/l, pH 6Á5), NaCl (1Á2 mol/l), and DTT (1 mmo/l). Eluted dynamin was dialysed against buffer containing HEPES (20 mmo/l, pH 7Á4), NaCl (1Á5 mol/l), DTT (1 mmo/l) and Glycerol (50%). Sample purity was checked using SDS-PAGE and samples were stored at À80°C until use. GTPase activity was measured using a plate-based malachite green colorimetric assay for free phosphate. Dynamin was assayed in Tris (5 mmo/l, pH 7Á4), NaCl (30 mmo/l), MgCl 2 (2 mmo/l), Tween 80 (0Á05% v/v), GTP (150 mmo/l), Leupeptin (1 lg/ml), PMSF (1 mmo/l) and incubated at 37°C. The incubation time and concentrations of dynamin and phosphatidylserine (PS) liposomes used vary and are stated throughout the text. Where required PS liposomes were extruded through filters of specific pore sizes prior to use.
Cell culture and transfection
HEK-293 cells were maintained in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum and penicillin/streptomycin. Transfection of EGFP-Dnm2 constructs was performed using TransIT-LTI Transfection Reagent (Mirus Bio LLC, Madison, WI, USA).
Transferrin uptake and recycling
Bone marrow or transfected HEK-293 cells were stained with Tf Alexa Fluor-647 conjugate (T-23366; Life Technologies Australia, Scoresby, Australia) for 30 min at 4°C. Uptake was performed at 37°C at the indicated time points, acid stripped (150 mmo/l NaCl, 20 mmo/l CaCl 2 and 20 mmo/l NaAc, pH 4Á6) and analysed by flow cytometry using a BD FACSCanto TM II flow cytometer and BD FACSDIVA TM software (BD Biosciences Australia, North Ryde, Australia). Tf uptake was calculated by dividing the relative intensity of Tf by the noninternalised Tf staining control without acid stripping. For recycling, following Tf uptake and acid stripping, cells were chased with 100 lg/ml non-fluorescent halo-Tf (T4132; Sigma-Aldrich) at 37°C at the indicated time points, acid washed and analysed by flow cytometry.
Immunofluorescence microscopy
Cells used for Tf uptake were fixed onto Superfrost Plus slides (Thermo Fischer Scientific, Braunschweig, Germany) with 4% paraformaldehyde, permeabilised and blocked. Primary antibodies used were anti-clathrin (ab21679; Abcam Austrailia, Melbourne, Austrailia) and anti-rab5 (ab18211; Abcam Austrailia). Cells were stained with the appropriate Alexa Fluor-555 secondary antibody (Life Technologies Austrailia) and nuclei were stained with 4,6-diamidino-2-phenylindole dihydrochloride (DAPI, D1306; Life Technologies Austrailia). Immunofluorescence was detected on a Nikon â A1r Plus inverted confocal microscope using the NIS-Elements Microscope Imaging Software (Nikon â Instruments Inc., Rhodes, Australia).
Statistical analysis
Where applicable, results were expressed as the mean AE standard deviation. For statistical analysis, the 2-tailed Student's t-test was employed unless otherwise stated, where *P < 0Á05; **P < 0Á01; ***P < 0Á001 or as defined in the figure legends.
Results
Identification of a novel mouse model of microcytic anaemia
In an ENU mutagenesis screen to identify genes regulating erythropoiesis (Rank et al, 2009; Brown et al, 2013 Brown et al, , 2015 , a G 1 mouse (RBC12) was identified with a mean cell volume (MCV) that was more than three standard deviations lower than that of the overall G 1 population (MCV 38 fl vs. 44Á9 fl). When the founder animal was mated with wild-type C57BL/6, c. 50% of pups born exhibited a reduced MCV, indicating that the phenotype was heritable, dominant and highly penetrant. RBC12 heterozygotes (denoted RBC12 +/M ) had a mild microcytic anaemia with reduced mean cellular haemoglobin (MCH), but normal mean cell haemoglobin concentration and red cell distribution width (Table I) . Red cell number and reticulocyte percentage were unchanged, as were leucocyte and platelet counts. Peripheral blood smears were relatively normal, with occasional hypochromic red cells and target cells observed ( Fig 1A) . Spleens from heterozygous mice exhibited a size and architecture equivalent to wild-type counterparts (Fig S1A) , but contained a twofold increase in proerythroblasts defined by CD71 Bright TER119 Dim cell surface expression (Fig 1B) . Erythroid progenitor numbers were unchanged, as was the response to haemolytic anaemia induced by treatment with phenylhydrazine (PHZ) (Fig S1B-C) . Given the mild changes in red cell morphology, the data suggested a defect in haem or iron metabolism, rather than globin production, as the most likely cause of the microcytic anaemia. However, iron studies, including TIBC and assessment of serum levels of iron, ferritin and Tf, were normal (Table I) .
RBC12 mice harbour a mutation in the large GTPase Dynamin 2
Following a genome-wide scan and SNP-based fine mapping, the RBC12 mutation was isolated to a 6Á71 Mb region on chromosome 9 that contains 194 genes (Fig S2) . Since almost all ENU-induced mutations that result in a phenotype occur within exons (Bauer et al, 2015) , a Roche-NimbleGen custom capture genomic array was designed to target all exons (including splice-site and some limited intronic sequences) within the interval, achieving 80% coverage of the target bases. Massively parallel sequencing of an affected animal identified a single T to G mutation in exon 6 of the large GTPase protein, Dnm2, which was validated by Sanger sequencing of multiple affected RBC12 animals (Fig 2A) . This point mutation was predicted to encode a valine to glycine amino acid substitution at position 235, located within the GTPase domain (Fig 2B) . This valine residue is conserved across all human and mouse DNM2 isoforms and all members of the classical Dynamins (DNM1-3). Hereafter, the RBC12 mouse strain is denoted Dnm2 V235G .
We next investigated the effect of the V235G mutation on Dnm2 mRNA and DNM2 protein levels in murine haematopoietic organs. q-PCR from adult Dnm2 +/V235G spleens demonstrated normal Dnm2 mRNA expression, suggesting the mutation does not affect mRNA stability (Fig 2C) . In contrast, DNM2 protein levels in splenocytes from Dnm2 +/V235G mice were approximately half that of wild-type littermates (Fig 2D) . These data suggest that the mutation affects protein stability.
The V235G mutation is not a simple loss of function
To determine whether the microcytic anaemia in Dnm2 +/ V235G mice could be explained by a simple 50% loss of Dnm2 function, we examined blood parameters in mice carrying an independently-derived constitutive knockout allele of Dnm2 as described previously (Ferguson et al, 2009) . No red cell abnormalities were detected in Dnm2 +/À mice ( Table S1 ), suggesting that the Dnm2 +/V235G mutation is not just a loss of function allele. We next examined mice heterozygous for the centronuclear muscular dystrophy Dnm2 R465W mutation, and found they had a mild anaemia that was normocytic, rather than microcytic (Table S1 ). Collectively, these results suggest that the V235G mutation in Dnm2 produces a protein that gains function and/or has dominant negative effects. Homozygous deletion of Dnm2 is embryonic lethal prior to day 8 (Ferguson et al, 2009 embryos die from non-haematopoietic defects.
Given the Dnm2 V235G mutation was a germline mutation present in all tissues, we determined if the red cell phenotype of Dnm2 +/V235G mice was intrinsic to haematopoietic cells.
Dnm2
+/V235G bone marrow cells were transplanted into wildtype control mice for reciprocal bone marrow transplants (Fig 2E) . Chimeric mice reconstituted with Dnm2
bone marrow exhibited microcytic anaemia 4-weeks posttransplantation. In contrast, red cell indices in Dnm2
animals reconstituted with wild-type bone marrow cells were normalised. These data indicate that the red cell defect in Dnm2 +/V235G mice has its origins in the haematopoietic system.
The V235G mutation in DNM2 impairs receptormediated endocytosis
Based upon the crystal structure of DNM1 (Faelber et al, 2011; Ford et al, 2011) , valine 235 in DNM2 is a key residue located within the nucleotide binding pocket (Fig 3A) . Specifically, V235 lines the pocket and contacts the guanine head group, and resides immediately N-terminal to a key loop that undergoes conformational change in response to GTP binding. DNM2-mediated vesicle scission has previously been shown to require both DNM2 self-assembly and GTP hydrolysis (Hinshaw & Schmid, 1995; Warnock et al, 1996) , which can be investigated in vitro using GTPase assays. To assess this in the V235G mutation, we performed a stimulated GTPase assay with recombinant wild-type and mutant DNM2 (expressed in Sf21 insect cells and purified by Amphiphysin 2 SH3 domain affinity chromatography). In the absence of phospholipid (PS liposomes), the GTPase activity of both forms of the protein was similar until 60 min, with DNM2-V235G failing to match wild-type activity thereafter (Fig 3B) , indicative of defective DNM2 self-assembly and ring formation with the V235G protein. In contrast, DNM2 assembly-stimulated GTP hydrolysis, measured in the presence of PS, was significantly increased in DNM2-V235G relative to wild-type (Fig 3B) . These findings combined, suggest the V235G mutation perturbs GTPase activity, consistent with the Dnm2 V235G allele not being a straight loss of function.
We then examined TfR uptake by flow cytometry of a Tf Alexa-Fluor conjugate, to determine if the V235G mutation affected CME in erythroid cells. Bone marrow cells from 10-week old Dnm2 +/V235G mice displayed a 50% reduction in Tf uptake by flow cytometry compared to cell from wild-type littermate controls (Fig 3C) , suggesting the V235G mutation impairs TfR-mediated endocytosis. To further examine the functional effects of the V235G mutation on endocytosis, and compare it with other mutations seen in CMT (K562E) and CNM (R465W), we generated EGFP-tagged DNM2 plasmids for expression in HEK293 cells. A mock transfection with the empty vector was included to control for endogenous DNM2 expression. Equivalent expression of wild-type and mutant variants of DNM2 was confirmed by Western blot (Fig 4A and data not shown) . Similar to cells expressing the DNM2-K44A dominant negative mutant, Tf uptake was almost undetectable in those expressing DNM2-V235G (Fig 4B) , suggesting it also acts in a dominant negative manner. The inhibition of endocytosis was similar in cells expressing the DNM2-K562E CMT mutation. In contrast, the DNM2-R465W mutation did not affect endocytosis. To examine the effect of the DNM2-V235G mutation on endosome recycling, we measured the rate of loss of fluorescently labelled intracellular Tf. Dnm2 +/V235G erythroid cells (data not shown) and all DNM2 overexpressing HEK293 cells (Fig 4C) cleared Tf at a similar rate, suggesting that the Dnm2 V235G mutation does not affect endosome recycling.
Using confocal microscopy, we next examined how the DNM2-V235G mutation affected the dynamics of endocytosis. CCPs were successfully formed in all DNM2 mutants after 1 min of Tf uptake based on co-staining of Tf and clathrin (Fig S3) , however after 5 min of Tf uptake, CME only occurred in cells expressing wild-type, or endogenous, DNM2 (negative GFP staining). The latter was illustrated by the lack of co-staining with the early endosomal marker, Rab5, in DNM2-V235G and DNM2-K44A expressing cells, where 4Á3% and 11Á1% of cells had Tf-Rab5 co-staining respectively compared to 75% of Dnm2-WT cells (Fig 5) . Taken together, these results indicate that the V235G mutation impairs early endosomal formation of the TfR-Tf CCT.
Microcytosis is not the result of iron deficiency
Given the important role of the Tf cycle in iron metabolism, iron deficiency presented as the most likely explanation for the microcytic anaemia. Given the normal serum iron studies, we therefore evaluated two more sensitive measures of iron deficiency: Zn protoporphryin and red cell ferritin. As a positive control, we evaluated iron stores in another ENUinduced mutant mouse strain that had a T to G nucleotide substitution at position 1934 in TfR1, resulting in a leucine to arginine substitution at amino acid 645 (L645R). This mutation resides in the ligand-binding domain of TfR1 that is responsible for binding Tf, and results in haematochromatosis (HFE) (Fig 6A) . Timed pregnancies of heterozygous intercrosses revealed that homozygotes died by embryonic day 10Á5-12Á5 due to lack of erythropoiesis (Fig 6B) with reduced expression of CD71 assessed by flow cytometry (Fig 6C) . Heterozygotes (TfR1 +/L645R ) exhibited modest perturbations in a number of red cell indices compared to Dnm2 +/V235G mice, with a marked increase in red cell count, and microcytic normochromic anaemia (Table II) . Red cell morphology was relatively normal (Fig 6C) . Similar to Dnm2 +/V235G mice, routine iron studies in TfR1 +/L645R animals revealed no abnormalities (Table II) . However, there was evidence of red cell iron deficiency with reduced red cell ferritin and elevated Zn protoporphyrin/haem ratio (Table II) . In contrast, all measures of iron stores in Dnm2 +/ V235G mice were normal (Table III) , which suggested that iron deficiency was unlikely to be the mechanism of microcytosis despite the impaired Tf endocytosis.
Discussion
In this study we provide the first evidence for Dnm2 function in the development of mature erythrocytes. Heterozygous mutants of Dnm2 exhibit a cell autonomous microcytic anaemia with defects in Tf uptake. Furthermore, homozygotes are incompatible with life prior to haematopoiesis, which demonstrates an essential role for the GTPase domain of Dnm2 function in early embryogenesis. DNM2 regulates a variety of cellular processes through CME and mutations have been well documented in the pathogenesis of CNM and CMT although mutations in the GTPase domain have not been identified in either disease. However, in the setting of cancer, recurrent mutations in all DNM2 domains including the GTPase domain are found in T-cell acute lymphoblastic leukaemia (Zhang et al, 2012; Neumann et al, 2013; Ge et al, 2016) . Consequently, when Dnm2 V235G animals were bred onto the Lmo2 oncogenic background, T-ALL development was accelerated in vivo with enhanced IL7 receptor signalling due to impaired CME (Tremblay et al, 2016) . Abnormalities in the genes involved in CME have been previously implicated in mouse models of anaemia. Mutation of the clathrin adaptor protein, PICALM, was identified in two ENU mutants displaying significant anaemia due to defects in iron metabolism (Potter et al, 1997; Klebig et al, 2003) . Similarly, Picalm knockout mice (Suzuki et al, 2012) and conditionally deleted haematopoietic Picalm mice (Ishikawa et al, 2015) demonstrated impaired iron uptake in erythroid cells due to deficient TfR-mediated endocytosis. Studies in these animals demonstrated a cellular-specific effect for regulation by endocytosis given that myeloid and lymphoid lineages were largely unaffected by Picalm deficiency, consistent with our findings in Dnm2 V235G animals and, indeed, other studies involving disease-specific pathogenesis of DNM2 mutations in human CNM and CMT (Koutsopoulos et al, 2011; Bohm et al, 2012) . Similarly, platelet-specific deletion of Dnm2 resulted in defective endocytosis of the thrombopoietin receptor, Mpl, leading to constitutive activation of JAK2 (Bender et al, 2015) . We have not yet elucidated the mechanism for the microcytic anaemia observed in Dnm2 +/V235G animals. Given that iron studies in Dnm2 +/V235G animals were unchanged (Tables I and III) , and given the contrasting abnormal levels of RBC ferritin, Tf saturation and ZnPP/Haem detected in TfR1 +/L645R animals (Table II) , our results suggest that Dnm2 is probably required for a function other than erythroid iron uptake. Our studies confirmed the V235G mutation leads to loss of GTPase activity, critical for Dnm2 function, which led to impaired Tf uptake in functional endocytic assays (Fig 2) . Therefore it was surprising that Dnm2 +/V235G animals displayed no apparent iron defect. In the case of a heterozygous mutation, where CME is not entirely blocked, one could postulate that adequate iron from the functioning allele sustains normal erythropoiesis in Dnm2 +/V235G animals. However, our in vitro studies showing the V235G mutation functions similarly to the DNM2-dead mutant, K44A (Fig 4) , and that heterozygous Dnm2 knockout animals display normal red blood cells (Table S1 ), indicating the V235G mutation is not simply loss of function. Conversely, it is unknown whether Tf-bound iron can be taken up in cells via a clathrin-independent mechanism. Transferrin receptor is not the sole molecule utilising CME for normal function in developing erythrocytes. Receptor-mediated endocytosis of the erythropoietin receptor (EpoR) is essential for normal recycling of the receptor during EPO signalling (Sulahian et al, 2009 ). However, Epo-and EpoR-deficient animals present with normocytic normochromic anaemia with reduced colony-forming ability, unlike Dnm2 +/V235G animals (Zeigler et al, 2010) . Alternatively, CME has been shown to play an essential role in erythrocyte enucleation, and in vitro inhibition of dynamin, using dynasore and MiTMAB, leads to defects in enucleation and haemoglobinisation in primary murine erythroblasts (Keerthivasan et al, 2010) . Further studies are required to discern the defective signalling pathway in Dnm2 V235G animals. The development of a conditional knock-in mouse model of the V235G mutation would enable the study of homozygotes. We cannot exclude a non-CME function for DNM2 in erythrocyte development. The erythrocyte membrane consists of a composite structure of phospholipids and skeletal proteins. Consistent with this, DNM2 has been shown to regulate both ACTB (b-actin) and phosphoinositides (Klein et al, 1998; Gomez et al, 2005) . Although a role for DNM2 in erythrocyte membrane homeostasis has not been described, mouse models of erythrocyte membrane instability have previously presented with a microcytic, non-haemolytic anaemia (Moyer et al, 2010) , consistent with the Dnm2 V235G phenotype. Alternatively, depletion of Ccnd3 ICyclin D3), causing cell cycle defects and macrocytosis in mice, shows that dysregulation of cell cycle can affect red cell size and number during terminal erythropoiesis (Sankaran et al, 2012) . Given the role of DNM2 in cytokinesis (Konopka et al, 2006) , whether DNM2 regulates erythrocyte cell division will be the focus of future studies. Two families with CMT also presented with neutropenia and/or pancytopenia (Zuchner et al, 2005) . Whilst individuals with DNM2 mutations have not been associated with red cell abnormalities, our study provides a strong rationale to sequence DNM2 in families with unexplained cases of microcytic anaemia. Fig S2. Mapping the RBC12 mutation. Fig S3. The V235G mutation does not alter the formation of clathrin coated pits. Table SI . Full blood examination of Dnm2 heterozygotes and Dnm2 +/R465W knock-in mice. 
